A study has uncovered a novel method to enhance immunotherapy for melanoma by targeting a protein known as macrophage receptor with collagenous structure, or MARCO. The findings showed that blocking MARCO in combination with anti-CTLA4 therapy appreciably slows tumor progression in melanoma. The findings were reported in Journal for ImmunoTherapy of Cancer.
Melanoma News
Pembrolizumab Plus Bevacizumab Shows Promise for Melanoma Brain Metastases
The anti–PD-1/VEGF combination of pembrolizumab and bevacizumab elicited strong clinical activity in patients with melanoma brain metastases.
iOnctura commences randomized Phase II study in metastatic uveal melanoma
GENEVA and AMSTERDAM, March 20, 2025 /PRNewswire/ — iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first patient in the randomized Phase II OCULE-01 study investigating lead asset roginolisib in patients with metastatic uveal melanoma (UM), a rare cancer of the eye.
New potential nanocarrier cancer vaccine could rescue immune response against melanoma
Researchers have created a new vaccine for the treatment of late-stage metastatic melanoma, an aggressive skin cancer that can resist conventional treatments because it exists in an ecosystem that suppresses the body’s immune response.